
A
HR+ HER2- breast cancer
n = 126
ESR1 (12.7%)
PIK3CA & ESR1 (13.5%)
PIK3CA (20.6%)
B
Colorectal cancer
n = 135
MET amp (0.7%)
EGFR ECD (2.2%)
EGFR amp (2.2%)
ERBB2 amp (3.0%)
BRAF (3.7%)
NRAS (8.9%)
PIK3CA (10.4%)
KRAS (37.8%)